ArticleJournal of oral and maxillofacial pathology : JOMFP
DNA methylation biomarkers as an early diagnostic tool in the progression of oral squamous cell carcinoma.
Article in Journal of oral and maxillofacial pathology : JOMFP. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oral squamous cell carcinoma (OSCC) remains a significant global health burden, with early detection being critical for improving outcomes. Aberrant DNA methylation of tumour suppressor genes has emerged as a promising biomarker for early oral carcinogenesis. This study investigates the methylation status of p16, DAPK, and MGMT genes in OSCC, leukoplakia, and adjacent normal tissues. Methods: Tissue samples from 18 patients were collected from a single contiguous field, including clinically normal mucosa, leukoplakia, and OSCC lesions. DNA was extracted and subjected to bisulfite conversion followed by methylation-specific PCR (MS-PCR). Methylation patterns were analysed for frequency, statistical association (Chi-square), and diagnostic performance (sensitivity and specificity). Results: DAPK showed progressive and statistically significant promoter methylation from normal to OSCC ( Conclusion: Among the three genes studied, DAPK emerged as a reliable biomarker for early OSCC detection. The findings support its integration into methylation-based screening panels, while MGMT and p16 may serve as complementary markers. Further large-scale studies are recommended to validate their clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.